High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

Caocci, G.; Vignetti, M.; Patriarca, A.; Breccia, M.; Platzbecker, U.; Palumbo, G. A.; Stauder, R.; Cottone, F.; Petranovic, D.; Voso, M. T.; Tafuri, A.; Invernizzi, R.; Caers, Jo; Luppi, M.; La Nasa, G.; Niscola, P.; Efficace, F.

doi:10.1007/s12185-020-02920-y

Article (Scientific journals)

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

Caocci, G.; Vignetti, M.; Patriarca, A. et al.

2020 • In International Journal of Hematology, 112, p. 141-146

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/249346

DOI
10.1007/s12185-020-02920-y

PubMed
32588394

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Caers 2020-s12185-020-02920-y.pdf

Publisher postprint (667.3 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Functional status; Myelodysplastic syndromes; Quality of life; Serum ferritin; Symptoms; Transfusions

Abstract :

[en] We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains. © 2020, Japanese Society of Hematology.

Disciplines :

Hematology

Author, co-author :

Caocci, G.; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy

Vignetti, M.; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy

Patriarca, A.; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

Breccia, M.; Department of Cellular Biotechnologies and Hematology, Division of Hematology, Sapienza University, Rome, Italy

Platzbecker, U.; Clinic and Policlinic of Hematology and Cellular Therapy, Oncology and Hemostaseology, University Hospital Leipzig, Leipzig, Germany

Palumbo, G. A.; Dipartimento di Scienze Mediche, Chirurgiche E Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy

Stauder, R.; Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

Cottone, F.; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy

Petranovic, D.; Department of Hematology, Clinical Hospital Center Rijeka, Rijeka, Croatia

Voso, M. T.; Department of Biomedicine and Prevention, Università di Roma “Tor Vergata”, Rome, Italy

More authors (7 more)

Language :

English

Title :

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

Publication date :

2020

Journal title :

International Journal of Hematology

ISSN :

0925-5710

Publisher :

Springer

Volume :

112

Pages :

141-146

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 07 July 2020

Statistics

Number of views

124 (3 by ULiège)

Number of downloads

142 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M. Dyserythropoiesis of myelodysplastic syndromes. Curr Opin Hematol. 2017;24(3):191–7. DOI: 10.1097/MOH.0000000000000325
Lyle L, Hirose A. Iron Overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment. J Adv Pract Oncol. 2018;9(4):392–405.
Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et al. Iron toxicity - Its effect on the bone marrow. Blood Rev. 2018;32(6):473–9. DOI: 10.1016/j.blre.2018.04.004
Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55–63. DOI: 10.1007/s12185-017-2367-1
Wood JC. Guidelines for quantifying iron overload. Hematol Am Soc Hematol Edu. 2014;2014(1):210–5. DOI: 10.1182/asheducation-2014.1.210
Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–64. DOI: 10.1182/blood-2013-03-492884
Caocci G, La Nasa G, Efficace F. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol. 2009;2(1):69–80. DOI: 10.1586/17474086.2.1.69
Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res. 2017;56:88–95. DOI: 10.1016/j.leukres.2017.01.033
Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, et al. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Support Palliat Care. 2016;6(1):80–8. DOI: 10.1136/bmjspcare-2014-000726
Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, et al. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia. 2020;2:13–7. 10.1038/s41375-41020-40746-41378. DOI: 10.1038/s41375-41020-40746-41378
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. DOI: 10.1093/jnci/85.5.365
Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96. DOI: 10.1200/JCO.2010.28.0107
Fozza C, La Nasa G, Caocci G. The Yin and Yang of myelodysplastic syndromes and autoimmunity: the paradox of autoimmune disorders responding to therapies specific for MDS. Crit Rev Oncol Hematol. 2019;142:51–7. DOI: 10.1016/j.critrevonc.2019.07.018
Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–92. DOI: 10.1038/s41375-018-0089-x
Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168(3):361–70. DOI: 10.1111/bjh.13138
Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105(3):640–51. DOI: 10.3324/haematol.2018.212332